share_log

INVO Bioscience | 8-K: INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

INVO Bioscience | 8-K: INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

INVO Bioscience | 8-K:INVO公佈了創紀錄的2024年第二季度財務業績,收入增長了481%,調整後的息稅折舊攤銷前利潤增長了110萬美元
美股SEC公告 ·  2024/08/15 04:14
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息